Fatigue after initiating rivaroxaban for venous thromboembolism

BACKGROUND: Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaban has be...

Descripción completa

Detalles Bibliográficos
Autores principales: Karlsvik, Tina Margrethe, Borgenvik, Thore Langfeldt, Aadalen, Mirjam, Utne, Kristin, Førsund, Eli, Jørgensen, Camilla Tøvik, Holst, René, Jelsness‐Jørgensen, Lars‐Petter, Ghanima, Waleed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article: Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292653/
https://www.ncbi.nlm.nih.gov/pubmed/32548556
http://dx.doi.org/10.1002/rth2.12312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292653/
https://www.ncbi.nlm.nih.gov/pubmed/32548556
http://dx.doi.org/10.1002/rth2.12312

Ejemplares similares